Launch of the New Cobas m 511 Analyser Marks a New Era in Haematology Testing

Integrated haematology analyser is now available for countries accepting the CE Mark

On 23 January 2017, Roche announced that its new, dedicated haematology testing solution, the cobas m 511 integrated haematology analyser, is now available for countries accepting the CE Mark. The cobas m 511, uses a unique approach to enter the new field of digital haematology through patented Bloodhound® technology for printing, staining and imaging. This technology uses only 30µL of blood to print a monolayer onto the slide, stains with an improved method for further analysis of the morphology and enables classification of cells displayed on a Viewing Station.

Contrary to the commonly used indirect methods in blood analysis today - primarily impedance and flow cytometry - the cobas m 511 images individual cells directly. Based on these direct images, the Bloodhound® technology counts, analyses morphology and then classifies every cell in the viewing area to provide a standard complete blood count and 5-part differential and reticulocyte count. While haematologists will continue to have the option of looking at slides under their microscopes; the cobas m 511 provides cell-by-cell images that, in many cases, may eliminate the need for microscopic review.

This launch marks the entry for Roche Diagnostics in the haematology market, with a Roche developed system.

Currently, haematology testing requires a larger blood sample from a given patient, which needs to be run across several different systems in order to get the full set of results. This is labour- and time-intensive, and potentially provides inconsistent results, as slide images are difficult to interpret.

Featuring Bloodhound® technology, the cobas m 511 addresses the challenges of haematology testing by combining the three components of the process: a digital morphology analyser, cell counter and classifier into one streamlined solution which prepares, stains and analyses microscopy blood slides.

The cobas m 511 provides greater accuracy and consistency of results, compared to current technologies, by identifying, counting, isolating and categorising white blood cells, red blood cells and platelets, then presenting the digital images of all these cell types. Medical technologists can now concentrate their time on finding and classifying abnormal cells within patient samples. This automation and digitalization reduces the need for resource-intensive manual microscope reviews, supports clinicians to share challenging cases around the world and enables the delivery of quicker results, which ultimately aid patient diagnoses.